全文获取类型
收费全文 | 200322篇 |
免费 | 13128篇 |
国内免费 | 640篇 |
专业分类
林业 | 22583篇 |
农学 | 13768篇 |
基础科学 | 2918篇 |
39318篇 | |
综合类 | 9441篇 |
农作物 | 16893篇 |
水产渔业 | 15336篇 |
畜牧兽医 | 65587篇 |
园艺 | 6124篇 |
植物保护 | 22122篇 |
出版年
2021年 | 2375篇 |
2020年 | 2771篇 |
2019年 | 3568篇 |
2018年 | 3556篇 |
2017年 | 3904篇 |
2016年 | 4490篇 |
2015年 | 4117篇 |
2014年 | 5468篇 |
2013年 | 15991篇 |
2012年 | 4615篇 |
2011年 | 6119篇 |
2010年 | 6622篇 |
2009年 | 7344篇 |
2008年 | 5635篇 |
2007年 | 4568篇 |
2006年 | 5482篇 |
2005年 | 4707篇 |
2004年 | 4620篇 |
2003年 | 4400篇 |
2002年 | 3783篇 |
2001年 | 3847篇 |
2000年 | 3520篇 |
1999年 | 3762篇 |
1998年 | 3913篇 |
1997年 | 3981篇 |
1996年 | 3728篇 |
1995年 | 4249篇 |
1994年 | 3629篇 |
1993年 | 3327篇 |
1992年 | 3033篇 |
1991年 | 3163篇 |
1990年 | 2850篇 |
1989年 | 2820篇 |
1988年 | 2443篇 |
1987年 | 2500篇 |
1986年 | 2368篇 |
1985年 | 2806篇 |
1984年 | 2811篇 |
1983年 | 2747篇 |
1982年 | 2474篇 |
1981年 | 2444篇 |
1980年 | 2446篇 |
1979年 | 2347篇 |
1978年 | 2253篇 |
1977年 | 2169篇 |
1976年 | 2014篇 |
1975年 | 1756篇 |
1974年 | 1755篇 |
1973年 | 1694篇 |
1971年 | 1436篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Pharmacokinetic profiles of the two major active metabolites of metamizole (dipyrone) in cats following three different routes of administration
下载免费PDF全文
![点击此处可从《Journal of veterinary pharmacology and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
B. Lebkowska‐Wieruszewska T. W. Kim B. Chea H. Owen A. Poapolathep M. Giorgi 《Journal of veterinary pharmacology and therapeutics》2018,41(2):334-339
This study was performed to determine pharmacokinetic profiles of the two active metabolites of the analgesic drug metamizole (dipyrone , MET), 4‐methylaminoantipyrine (MAA), and 4‐aminoantipyrine (AA), after intravenous (i.v., intramuscular (i.m.), and oral (p.o.) administration in cats. Six healthy mixed‐breed cats were administered MET (25 mg/kg) by i.v., i.m., or p.o. routes in a crossover design. Adverse clinical signs, namely salivation and vomiting, were detected in all groups (i.v. 67%, i.m. 34%, and p.o. 15%). The mean maximal plasma concentration of MAA for i.v., i.m., and p.o. administrations was 148.63 ± 106.64, 18.74 ± 4.97, and 20.59 ± 15.29 μg/ml, respectively, with about 7 hr of half‐life in all routes. Among the administration routes, the area under the plasma concentration curve (AUC) value was the lowest after i.m. administration and the AUCEV/i.v. ratio was higher in p.o. than the i.m. administration without statistical significance. The plasma concentration of AA was detectable up to 24 hr, and the mean plasma concentrations were smaller than MAA. The present results suggest that MET is converted into the active metabolites in cats as in humans. Further pharmacodynamics and safety studies should be performed before any clinical use. 相似文献
993.
Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences
下载免费PDF全文
![点击此处可从《Journal of veterinary pharmacology and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
L. Dencker R. T. Cristina H. Linden I. Schmerold 《Journal of veterinary pharmacology and therapeutics》2018,41(3):378-383
The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. As a pan‐European organization, it brings together pharmaceutical societies as well as academic, industrial and regulatory scientists engaged in drug research and development, drug regulation and education of professionals working in these fields. EUFEPS represents pharmaceutical sciences in Europe and is recognized as such by both the European Commission and the European Medicines Agency. EUFEPS cooperates with the European Federation of Pharmaceutical Industries and other European organizations and maintains global connections with agencies such as the US Food and Drug Administration and the American Association of Pharmaceutical Scientists. EUFEPS has established specified networks forming the basis of its activities. The creation of a Network on Veterinary Medicines is prompted by the manifold problems resulting from the use of veterinary drugs and its inherent interconnections with human medicine, environmental and public health. A long‐term goal of this initiative was to expand the spectrum of available therapeutics for use in animals, including the development of innovative delivery systems. 相似文献
994.
Integration of pharmacokinetic–pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs
下载免费PDF全文
![点击此处可从《Journal of veterinary pharmacology and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Y. Wang A. Sajid S. Ahmed X. Li 《Journal of veterinary pharmacology and therapeutics》2018,41(5):706-718
The aims of this study were to establish optimal doses of doxycycline (dox) against Haemophilus parasuis on the basis of pharmacokinetic–pharmacodynamic (PK‐PD) integration modeling. The infected model was established by intranasal inoculation of organism in pigs and confirmed by clinical signs, blood biochemistry, and microscopic examinations. The recommended dose (20 mg/kg b.w.) was administered in pigs through intramuscular routes for PK studies. The area under the concentration 0‐ to 24‐hr curve (AUC0–24), elimination half‐life (T½ke), and mean residence time (MRT) of dox in healthy and H. parasuis‐infected pigs were 55.51 ± 5.72 versus 57.10 ± 4.89 μg·hr/ml, 8.28 ± 0.91 versus 9.80 ± 2.38 hr, and 8.43 ± 0.27 versus 8.79 ± 0.18 hr, respectively. The minimal inhibitory concentration (MIC) of dox against 40 H. parasuis isolates was conducted through broth microdilution method, the corresponding MIC50 and MIC90 were 0.25 and 1 μg/ml, respectively. The Ex vivo growth inhibition data suggested that dox exhibited a concentration‐dependent killing mechanism. Based on the observed AUC24 hr/MIC values by modeling PK‐PD data in H. parasuis‐infected pigs, the doses predicted to obtain bacteriostatic, bactericidal, and elimination effects for H. parasuis over 24 hr were 5.25, 8.55, and 10.37 mg/kg for the 50% target attainment rate (TAR), and 7.26, 13.82, and 18.17 mg/kg for 90% TAR, respectively. This study provided a more optimized alternative for clinical use and demonstrated that the dosage 20 mg/kg of dox by intramuscular administration could have an effective bactericidal activity against H. parasuis. 相似文献
995.
Pharmacokinetic assessment of the monepantel plus oxfendazole combined administration in dairy cows
下载免费PDF全文
![点击此处可从《Journal of veterinary pharmacology and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M. Ballent P. Viviani F. Imperiale P. Dominguez S. Halwachs H. Mahnke W. Honscha C. Lanusse G. Virkel A. Lifschitz 《Journal of veterinary pharmacology and therapeutics》2018,41(2):292-300
Monepantel (MNP) is a novel anthelmintic compound launched into the veterinary pharmaceutical market. MNP is not licenced for use in dairy animals due to the prolonged elimination of its metabolite monepantel sulphone (MNPSO2) into milk. The goal of this study was to evaluate the presence of potential in vivo drug‐drug interactions affecting the pattern of milk excretion after the coadministration of the anthelmintics MNP and oxfendazole (OFZ) to lactating dairy cows. The concentrations of both parent drugs and their metabolites were measured in plasma and milk samples by HPLC. MNPSO2 was the main metabolite recovered from plasma and milk after oral administration of MNP. A high distribution of MNPSO2 into milk was observed. The milk‐to‐plasma ratio (M/P ratio) for this metabolite was equal to 6.75. Conversely, the M/P ratio of OFZ was 1.26. Plasma concentration profiles of MNP and MNPSO2 were not modified in the presence of OFZ. The pattern of MNPSO2 excretion into milk was also unchanged in animals receiving MNP plus OFZ. The percentage of the total administered dose recovered from milk was 0.09 ± 0.04% (MNP) and 2.79 ± 1.54% (MNPSO2) after the administration of MNP alone and 0.06 ± 0.04% (MNP) and 2.34 ± 1.38% (MNPSO2) after the combined treatment. The presence of MNP did not alter the plasma and milk disposition kinetics of OFZ. The concentrations of the metabolite fenbendazole sulphone tended to be slightly higher in the coadministered group. Although from a pharmacodynamic point of view the coadministration of MNP and OFZ may be a useful tool, the presence of OFZ did not modify the in vivo pharmacokinetic behaviour of MNP and therefore did not result in reduced milk concentrations of MNPSO2. 相似文献
996.
Effects of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor velagliflozin,a new drug with therapeutic potential to treat diabetes in cats
下载免费PDF全文
![点击此处可从《Journal of veterinary pharmacology and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M. Hoenig M. Clark D. J. Schaeffer D. Reiche 《Journal of veterinary pharmacology and therapeutics》2018,41(2):266-273
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors are used in the treatment of human diabetics. They increase glucose excretion and correct hyperglycemia. We examined the investigational SGLT2 inhibitor velagliflozin in two groups of six neutered adult obese cats (equal gender distribution). Placebo (Pl) or drug (D; 1 mg/kg) was administered for 35 days. Routine blood examinations, fructosamine, beta‐hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), glucagon, adiponectin, and leptin were measured before and after treatment, also water intake, and urinary electrolytes, glucose, and volume. Indirect calorimetry, an intravenous glucose tolerance test (IVGTT; 0.8 g/kg) and insulin tolerance test (IVITT) were conducted. All cats tolerated treatment well. Significant changes with D included a decrease in the respiratory exchange ratio, an increase in cholesterol, a small increase in albumin, and a rise in BHB and NEFA. Glucose clearance was unaltered, although less insulin was secreted during the IVGTT (p = .056) suggesting improved insulin sensitivity. IVITT was unchanged. Treatment did not affect glucagon, leptin, or adiponectin. Water intake, urine output, urinary glucose excretion, and the glucose/creatinine ratio but not urinary electrolytes were significantly higher post‐D. We conclude that velagliflozin is a promising drug, which increases urinary glucose excretion in cats and could thereby be beneficial for the treatment of hyperglycemia. 相似文献
997.
O. L. Levionnois T. K. Fosse B. Ranheim 《Journal of veterinary pharmacology and therapeutics》2018,41(2):314-323
Flunixin is marketed in several countries for analgesia in adult swine but little is known about its efficacy in piglets. Thirty‐two piglets (6–8 days old) were randomized to receive placebo saline (n = 11, group CONTROL) or flunixin meglumine intravenously at 2.2 (n = 11, group MEDIUM) or 4.4 (n = 10, group HIGH) mg/kg, 10 hr after subcutaneous injection of kaolin in the left metacarpal area. A hand‐held algometer was used to determine each piglet’s mechanical nociceptive threshold (MNT) from both front feet up to 50 hr after treatment (cut‐off value of 24.5 newton). Serial venous blood samples were obtained to quantify flunixin in plasma using LC‐MS/MS. A PKPD model describing the effect of flunixin on the mechanical nociceptive threshold was obtained based on an inhibitory indirect response model. A two‐compartmental PK model was used. A significant effect of flunixin was observed for both doses compared to control group, with 4.4 mg/kg showing the most relevant (6–10 newton) and long‐lasting effect (34 hr). The median IC50 was 6.78 and 2.63 mg/ml in groups MEDIUM and HIGH, respectively. The ED50 in this model was 6.6 mg/kg. Flunixin exhibited marked antinociceptive effect on kaolin‐induced inflammatory hyperalgesia in piglets. 相似文献
998.
S. T. Elazab D. E. Schrunk R. W. Griffith S. M. Ensley G. Dell'Anna K. Mullin M. G. Elsayed M. S. Amer S. M. El‐Nabtity W. H. Hsu 《Journal of veterinary pharmacology and therapeutics》2018,41(3):374-377
The pharmacokinetics of cefquinome were studied in healthy and Pasteurella multocida‐infected rabbits after a single intramuscular (IM) injection at 2 mg/kg of its sulfate salt. Twelve female New Zealand white rabbits (2.0–2.5 kg) were used; six of them served as controls, and the other six had been infected with P. multocida; the experiments were conducted 1–2 days after nasal inoculation of P. multocida when rabbits showed the signs of respiratory infection. Plasma concentrations of cefquinome were determined using high‐performance liquid chromatography. The values of elimination half‐life, area under the curve, area under the first moment curve, and mean residence time were significantly lower in infected rabbits (0.48 hr, 4.54 hr*μg/ml, 3.63 hr* hr*μg/ml and 0.8 hr, respectively) than healthy rabbits (0.72 hr, 9.11 hr*μg/ml, 9.85 hr* hr*μg/ml and 1.1 hr, respectively), whereas total body clearance was significantly higher in infected than healthy rabbits. Therefore, P. multocida infection caused significant changes in some of the pharmacokinetic parameters of cefquinome in rabbits. These pharmacokinetic changes may affect dose regimen when used in P. multocida‐infected rabbits. 相似文献
999.
Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats
下载免费PDF全文
![点击此处可从《Journal of veterinary pharmacology and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
William Buhles Jessica M. Quimby Daizie Labelle Valentine S. Williams 《Journal of veterinary pharmacology and therapeutics》2018,41(5):644-651
Single and multiple dose pharmacokinetics (PK) of mirtazapine transdermal ointment applied to the inner ear pinna of cats were assessed. Study 1 was a randomized, cross‐over single dose study (n = 8). Cats were treated once with 0.5 mg/kg of mirtazapine transdermal ointment applied topically to the inner ear pinna (treatment) or administered orally (control) and then crossed over after washout. Plasma was collected predose and at specified intervals over 96 hr following dosing. Study 2 was a multiple dose study (n = 8). Cats were treated daily for 14 days with 0.5 mg/kg of mirtazapine transdermal ointment applied topically to the inner pinna. Plasma was collected on Day 13 predose and at specified intervals over 96 hr following the final dose. In Study 1, single transdermal administration of mirtazapine resulted in mean Tmax = 15.9 hr, Cmax = 21.5 ng/mL, AUC0‐24 = 100 ng*hr/mL, AUC0‐∞ = 260 ng*hr/mL and calculated half‐life = 26.8 hr. Single oral administration of mirtazapine resulted in mean Tmax = 1.1 hr, Cmax = 83.1 ng/mL, AUC0‐24 = 377 ng*hr/mL, AUC0‐∞ = 434 ng*hr/mL and calculated half‐life = 10.1 hr. Mean relative bioavailability (F) of transdermal to oral dosing was 64.9%. In Study 2, daily application of mirtazapine for 14 days resulted in mean Tmax = 2.1 hr, Cmax = 39.6 ng/mL, AUC0‐24 = 400 ng*hr/mL, AUC0‐∞ = 647 ng*hr/mL and calculated half‐life = 20.7 hr. Single and repeat topical doses of a novel mirtazapine transdermal ointment achieve measurable plasma concentrations in cats. 相似文献
1000.